Actively Recruiting
Screening for Intrapartum Fetal Compromise Using Placental Biomarkers
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2025-12-02
428
Participants Needed
2
Research Sites
183 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to investigate the association between placental markers (sFlt-1, PlGF, and the sFlt-1/PlGF ratio) and intrapartum fetal compromise, assessed on the basis of the cardiotocographic tracing.
CONDITIONS
Official Title
Screening for Intrapartum Fetal Compromise Using Placental Biomarkers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Gestational age of 32 weeks or more
- Provided informed consent for study participation and data processing
- Pregnant patients requiring placental marker testing as part of routine clinical care
- Planning to deliver at the Obstetrics Units of participating centers
You will not qualify if you...
- Absolute contraindications to vaginal delivery such as placenta previa, vasa previa, placenta accreta, or previous myomectomy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Bologna, Italy, 40138
Actively Recruiting
2
IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Milano, Italy, 20122
Not Yet Recruiting
Research Team
A
Antonio Farina, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here